WO2005004919A3 - Systemes de liberation prolongee destines a des antibiotiques macrolides - Google Patents

Systemes de liberation prolongee destines a des antibiotiques macrolides Download PDF

Info

Publication number
WO2005004919A3
WO2005004919A3 PCT/US2004/020620 US2004020620W WO2005004919A3 WO 2005004919 A3 WO2005004919 A3 WO 2005004919A3 US 2004020620 W US2004020620 W US 2004020620W WO 2005004919 A3 WO2005004919 A3 WO 2005004919A3
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
extended release
macrolide antibiotics
release systems
release
Prior art date
Application number
PCT/US2004/020620
Other languages
English (en)
Other versions
WO2005004919A2 (fr
WO2005004919A8 (fr
Inventor
Gopi M Venkatesh
Nehal H Vyas
Ken Kangyi Qian
Original Assignee
Eurand Inc
Gopi M Venkatesh
Nehal H Vyas
Ken Kangyi Qian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/658,078 external-priority patent/US20050053658A1/en
Application filed by Eurand Inc, Gopi M Venkatesh, Nehal H Vyas, Ken Kangyi Qian filed Critical Eurand Inc
Publication of WO2005004919A2 publication Critical patent/WO2005004919A2/fr
Publication of WO2005004919A3 publication Critical patent/WO2005004919A3/fr
Publication of WO2005004919A8 publication Critical patent/WO2005004919A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une forme dosifiée unitaire telle qu'un comprimé ou équivalent permettant la délivrance d'antibiotiques macrolides peu solubles dans l'eau, tels que la clarithromycine dans l'organisme avec une libération prolongée. Cette forme dosifiée unitaire est destinée à libérer le principe actif principalement par érosion du comprimé bien que la composition du comprimé ne contienne aucun agent de contrôle de la vitesse de dissolution, polymère ou esters d'acides gras. Ce Un tel système de délivrance de médicament procure une concentration de plasma profil dans le temps convenant à une transmission orale une fois par jour.
PCT/US2004/020620 2003-07-02 2004-06-28 Systemes de liberation prolongee destines a des antibiotiques macrolides WO2005004919A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48437203P 2003-07-02 2003-07-02
US60/484,372 2003-07-02
US10/658,078 2003-09-09
US10/658,078 US20050053658A1 (en) 2003-09-09 2003-09-09 Extended release systems for macrolide antibiotics

Publications (3)

Publication Number Publication Date
WO2005004919A2 WO2005004919A2 (fr) 2005-01-20
WO2005004919A3 true WO2005004919A3 (fr) 2005-03-17
WO2005004919A8 WO2005004919A8 (fr) 2005-08-04

Family

ID=34068193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/020620 WO2005004919A2 (fr) 2003-07-02 2004-06-28 Systemes de liberation prolongee destines a des antibiotiques macrolides

Country Status (1)

Country Link
WO (1) WO2005004919A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101152470B1 (ko) 2003-08-13 2012-06-01 바이오콘 리미티드 치료제용 마이크로-입자 지방산 염 고형 투약 제형
CN102813633A (zh) * 2011-06-10 2012-12-12 塔科敏斯基制药厂波尔法合资公司 用湿法制粒制备包含大环内酯类抗生素的药物组合物的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
WO2002017885A2 (fr) * 2000-08-29 2002-03-07 Ranbaxy Laboratories Limited Formulation a liberation controlee d'erythromycine ou de derive de cette substance
WO2002024174A2 (fr) * 2000-09-22 2002-03-28 Galephar M/F Composition a liberation prolongee contenant de la clarithromycine
WO2003017981A1 (fr) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Formulation a liberation controlee de clarithromycine ou de tinidazol
EP1302205A1 (fr) * 2001-10-01 2003-04-16 Ind-Swift Limited Composition pharmaceutique à libération contrôlée comprenant citrate de macrolide
WO2003053416A1 (fr) * 2001-12-21 2003-07-03 Pfizer Products Inc. Formulations d'azithromycine directement compressibles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
WO2002017885A2 (fr) * 2000-08-29 2002-03-07 Ranbaxy Laboratories Limited Formulation a liberation controlee d'erythromycine ou de derive de cette substance
WO2002024174A2 (fr) * 2000-09-22 2002-03-28 Galephar M/F Composition a liberation prolongee contenant de la clarithromycine
WO2003017981A1 (fr) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Formulation a liberation controlee de clarithromycine ou de tinidazol
EP1302205A1 (fr) * 2001-10-01 2003-04-16 Ind-Swift Limited Composition pharmaceutique à libération contrôlée comprenant citrate de macrolide
WO2003053416A1 (fr) * 2001-12-21 2003-07-03 Pfizer Products Inc. Formulations d'azithromycine directement compressibles

Also Published As

Publication number Publication date
WO2005004919A2 (fr) 2005-01-20
WO2005004919A8 (fr) 2005-08-04

Similar Documents

Publication Publication Date Title
WO2006113505A3 (fr) Systemes d'apport de substances pharmaceutiques destines a des medicaments hydrophobes et compositions comprenant ces derniers
ES2344954T3 (es) Preparacion en forma de pelicula para la liberacion bifasica de sustancias farmacologicamente activas u otras.
MXPA02007762A (es) Sistema de suministro de farmaco pulsativos temporalizados.
MXPA02006150A (es) Formulaciones de liberacion sostenida de un inhibidor de ciclooxigenasa-2.
WO2006017852A3 (fr) Compositions pharmaceutiques permettant la liberation progressive de composes bioactifs
BR0114633A (pt) Formulações farmacêuticas com liberação retardada
WO2002028376A3 (fr) Preparations a chrono-administration et methode d'utilisation
AU2002235155A1 (en) Crystallization inhibition of drugs in transdermal drug delivery systems
IL174562A0 (en) Oros push-stick for controlled delivery of active agent
BR0112532A (pt) Composição farmacêutica oral, sistema galênico e uso da composição
WO2002053100A3 (fr) Forme posologique d'administration orale de medicaments hydrophiles, tels qu'une heparine de faible poids moleculaire
WO2007000778A3 (fr) Compositions pharmaceutiques a liberation modifiee et leurs procedes
WO2006096806A3 (fr) Traitement avec une statine et des acides gras omega 3 et produit de combinaison correspondant
AR066313A2 (es) Una formulacion de liberacion controlada de galantamina, una forma farmaceutica de dosificacion, un proceso para la preparacion de dicha formulacion, y el uso de dicha formulacion para la manufactura de un medicamento
NZ603579A (en) Controlled release formulations
CN102325526A (zh) 延长释放的药物制剂
WO2004045578A3 (fr) Composes organiques
WO2004108162A3 (fr) Composition pharmaceutique et methode de traitement
SI1521572T1 (sl) Film, ki se da bioerodirati, za dajanje oftalmičnega zdravila
JP2007501248A5 (fr)
Baum et al. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate
WO2006060325A3 (fr) Formulations enrobees d'administration de medicaments
WO2002024203A3 (fr) Formulation à administrer oralement à libération contrôlée
CA2383212A1 (fr) Dosage oral a liberation regulee destine a l'administration orale
WO2007086079A3 (fr) Forme de dose a liberation soutenue de derives de phenothiazine contenant un canalisateur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

122 Ep: pct application non-entry in european phase